Nasdaq · Healthcare
Viridian Therapeutics, Inc.\DE (VRDN)
As-reported financials and recent SEC filings for Viridian Therapeutics, Inc.\DE, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$70.8M
Net income
$-342.6M
Net margin
—
Diluted EPS
—
ROE
-47.4%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $70.8M | $302,000 | $314,000 | $1.8M | $3.0M |
| Gross profit | — | — | — | — | — |
| Operating income | $-363.4M | $-299.0M | $-254.4M | $-134.3M | $-79.7M |
| Net income | $-342.6M | $-269.9M | $-237.7M | $-129.9M | $-79.4M |
| Diluted EPS | — | — | $-5.31 | $-4.05 | $-2.22 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-07-02
View on EDGAR →42026-07-02
View on EDGAR →42026-07-02
View on EDGAR →42026-07-02
View on EDGAR →42026-07-02
View on EDGAR →42026-07-02
View on EDGAR →8-K2026-06-29
View on EDGAR →SCHEDULE 13G2026-06-26
View on EDGAR →Largest Healthcare peers
Go deeper on VRDN
Search Viridian Therapeutics, Inc.\DE’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.